Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21660811 | 0.90 | HTT (0.39) | USP5PTGDR2RAB9AP2RX7POLB | |
| SCHEMBL21864004 | 0.87 | ALDH1A1 (0.41) | CHRM4RAB9AP2RX7ALDH1A1 | |
| SCHEMBL21660770 | 0.82 | EGLN1 (0.43) | USP5CHRM4EGLN1ALDH1A1 | |
| SCHEMBL21864003 | 0.81 | THRB (0.40) | POLBPKMALDH1A1FFAR4 | |
| SCHEMBL21864164 | 0.81 | PSMB5 (0.45) | P2RX7ALDH1A1 | |
| SCHEMBL21864019 | 0.78 | PSMB5 (0.60) | — | |
| SCHEMBL21660803 | 0.78 | KDM4E (0.44) | RAB9AP2RX7ALDH1A1 | |
| SCHEMBL21660817 | 0.78 | CHRM4 (0.45) | PTGDR2CHRM4EGLN2EGLN1EGLN3 | |
| SCHEMBL21863999 | 0.76 | ALDH1A1 (0.43) | RAB9APOLBPKMALDH1A1 | |
| SCHEMBL21661134 | 0.76 | CHRM2 (0.38) | USP5CHRM4EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014943-B2 | Azetidine derivative | CHIA TAI TIANQING PHARMACEUTICAL GROUP GO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20200115392-A1 | AZETIDINE DERIVATIVE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014943-B2 | Azetidine derivative | BCL9, MCL1, BCL9L | USP5 350/4885PTGDR2 971/4885CHRM4 3740/4885 |
| US-20200115392-A1 | AZETIDINE DERIVATIVE | BCL9, MCL1, BCL9L | USP5 350/4885PTGDR2 971/4885CHRM4 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.